Literature DB >> 8709244

Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles.

J A Turpin1, S J Terpening, C A Schaeffer, G Yu, C J Glover, R L Felsted, E A Sausville, W G Rice.   

Abstract

The Cys-Xaa2-Cys-Xaa4-His-Xaa4-Cys zinc fingers of retroviral nucleocapsid proteins are prime antiviral targets because of conservation of the Cys and His chelating residues and the absolute requirement of these fingers in both early and late phases of retroviral replication. We previously reported that certain disulfide-substituted benzamides (DIBAs) chemically modify the Cys residues of the fingers, resulting in inhibition of human immunodeficiency virus type 1 (HIV-1) replication (W. G. Rice, J. G. Supko, L. Malspeis, R. W. Buckheit, Jr., D. Clanton, M. Bu, L. Graham, C. A. Schaeffer, J. A. Turpin, J. Domagala, R. Gogliotti, J. P. Bader, S. M. Halliday, L. Coren, R. C. Sowder II, L. O. Arthur, and L. E. Henderson, Science 270:1194-1197, 1995). We now examine the consequences of the interaction of DIBAs with the zinc fingers of the HIV-1 p7 nucleocapsid protein and its Pr55gag precursor. In HIV-1-infected U1 cells, DIBAs inhibited the release of infectious virions, and even under conditions in which virion particles were produced, the particles were noninfectious. DIBAs caused abnormal processing of Gag precursors, and the inhibitory effect on processing was not due to inhibition of the HIV-1 protease enzyme or Pr55gag myristoylation. Rather, the defect in processing was due to the formation of intermolecular cross-linkages among the zinc fingers of adjacent Gag molecules, rendering the precursors no longer recognizable by HIV-1 protease. Likewise, DIBAs caused intermolecular cross-linkage among recombinant Pr55gag packaged into pseudovirions, thereby generating modified precursors that were resistant to the action of protease. Thus, DIBAs chemically modified the mutationally intolerant retroviral zinc fingers in infected cells, interrupting protease-mediated maturation of virions and leading ultimately to the production of compromised virions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8709244      PMCID: PMC190642          DOI: 10.1128/JVI.70.9.6180-6189.1996

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Potential metal-binding domains in nucleic acid binding proteins.

Authors:  J M Berg
Journal:  Science       Date:  1986-04-25       Impact factor: 47.728

2.  Trans-activation of the 5' to 3' viral DNA strand transfer by nucleocapsid protein during reverse transcription of HIV1 RNA.

Authors:  J L Darlix; A Vincent; C Gabus; H de Rocquigny; B Roques
Journal:  C R Acad Sci III       Date:  1993-08

3.  The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes.

Authors:  W G Rice; C A Schaeffer; L Graham; M Bu; J S McDougal; S L Orloff; F Villinger; M Young; S Oroszlan; M R Fesen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

4.  Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate.

Authors:  T M Folks; J Justement; A Kinter; S Schnittman; J Orenstein; G Poli; A S Fauci
Journal:  J Immunol       Date:  1988-02-15       Impact factor: 5.422

5.  Characterization of human immunodeficiency virus type 1 Pr55gag membrane association in a cell-free system: requirement for a C-terminal domain.

Authors:  E J Platt; O K Haffar
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

6.  Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor.

Authors:  R W Buckheit; M G Hollingshead; J Germany-Decker; E L White; J B McMahon; L B Allen; L J Ross; W D Decker; L Westbrook; W M Shannon
Journal:  Antiviral Res       Date:  1993-07       Impact factor: 5.970

7.  1H NMR structure and biological studies of the His23-->Cys mutant nucleocapsid protein of HIV-1 indicate that the conformation of the first zinc finger is critical for virus infectivity.

Authors:  H Déméné; C Z Dong; M Ottmann; M C Rouyez; N Jullian; N Morellet; Y Mely; J L Darlix; M C Fournié-Zaluski; S Saragosti
Journal:  Biochemistry       Date:  1994-10-04       Impact factor: 3.162

8.  Human immunodeficiency virus nucleocapsid protein accelerates strand transfer of the terminally redundant sequences involved in reverse transcription.

Authors:  J C You; C S McHenry
Journal:  J Biol Chem       Date:  1994-12-16       Impact factor: 5.157

9.  Analysis of the primary structure of the long terminal repeat and the gag and pol genes of the human spumaretrovirus.

Authors:  B Maurer; H Bannert; G Darai; R M Flügel
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

10.  Primary structure of the low molecular weight nucleic acid-binding proteins of murine leukemia viruses.

Authors:  L E Henderson; T D Copeland; R C Sowder; G W Smythers; S Oroszlan
Journal:  J Biol Chem       Date:  1981-08-25       Impact factor: 5.157

View more
  21 in total

1.  A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity.

Authors:  S Druillennec; C Z Dong; S Escaich; N Gresh; A Bousseau; B P Roques; M C Fournié-Zaluski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease.

Authors:  N Sheng; S C Pettit; R J Tritch; D H Ozturk; M M Rayner; R Swanstrom; S Erickson-Viitanen
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Reversal by dithiothreitol treatment of the block in murine leukemia virus maturation induced by disulfide cross-linking.

Authors:  Stephen Campbell; Masamichi Oshima; Jane Mirro; Kunio Nagashima; Alan Rein
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

4.  Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication.

Authors:  L Berthoux; C Péchoux; J L Darlix
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Delay of simian human immunodeficiency virus infection and control of viral replication in vaccinated macaques challenged in the presence of a topical microbicide.

Authors:  Cecilia Cheng-Mayer; Yaoxing Huang; Agegnehu Gettie; Lily Tsai; Wuze Ren; Madina Shakirzyanova; Silvana T Sina; Nataliya Trunova; James Blanchard; Lisa M Miller Jenkins; Yungtai Lo; Marco L Schito; Ettore Appella
Journal:  AIDS       Date:  2011-09-24       Impact factor: 4.177

6.  Covalent Antiviral Agents.

Authors:  Sako Mirzaie; Fatemeh Abdi; Amin GhavamiNejad; Brian Lu; Xiao Yu Wu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription.

Authors:  J A Turpin; R W Buckheit; D Derse; M Hollingshead; K Williamson; C Palamone; M C Osterling; S A Hill; L Graham; C A Schaeffer; M Bu; M Huang; W M Cholody; C J Michejda; W G Rice
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

8.  Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins.

Authors:  W G Rice; D C Baker; C A Schaeffer; L Graham; M Bu; S Terpening; D Clanton; R Schultz; J P Bader; R W Buckheit; L Field; P K Singh; J A Turpin
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

9.  A cooperative and specific DNA-binding mode of HIV-1 integrase depends on the nature of the metallic cofactor and involves the zinc-containing N-terminal domain.

Authors:  Kevin Carayon; Hervé Leh; Etienne Henry; Françoise Simon; Jean-François Mouscadet; Eric Deprez
Journal:  Nucleic Acids Res       Date:  2010-02-17       Impact factor: 16.971

10.  Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection.

Authors:  Gregory S Wallace; Cecilia Cheng-Mayer; Marco L Schito; Patricia Fletcher; Lisa M Miller Jenkins; Ryo Hayashi; A Robert Neurath; Ettore Appella; Robin J Shattock
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.